Document:

Exhibit 10.3

 

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights
Agreement (this “Agreement”) is made and entered into as of June 2, 2022, between Rockwell Medical, Inc., a Delaware
corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser”
and, collectively, the “Purchasers”).

 

This Agreement is made pursuant
to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).

 

The Company and each Purchaser
hereby agrees as follows:

 

1.        Definitions.

 

Capitalized terms used
and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase
Agreement. As used in this Agreement, the following terms shall have the following meanings:

 

“Advice”
shall have the meaning set forth in Section 6(c).

 

“Effectiveness
Date” means, with respect to the Initial Registration Statement required to be filed hereunder, the 60th calendar day following
the date hereof (or, in the event of a “full review” by the Commission, the 90th calendar day following the date hereof)
and with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), the 30th calendar
day following the date on which an additional Registration Statement is required to be filed hereunder (or, in the event of a “full
review” by the Commission, the 45th calendar day following the date such additional Registration Statement is required to be filed
hereunder); provided, however, that in the event the Company is notified by the Commission that one or more of the above
Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such
Registration Statement shall be the fifth Trading Day following the date on which the Company is so notified if such date precedes the
dates otherwise required above, provided, further, if such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness
Date shall be the next succeeding Trading Day.

 

“Effectiveness
Period” shall have the meaning set forth in Section 2(a).

 

“Event”
shall have the meaning set forth in Section 2(d).

 

“Event
Date” shall have the meaning set forth in Section 2(d).

 

     

     

    

 

“Filing
Date” means, with respect to the Initial Registration Statement required hereunder, the 30th calendar day following the date
hereof and, with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), the
earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the
Registrable Securities.

 

“Holder”
or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.

 

“Indemnified
Party” shall have the meaning set forth in Section 5(c).

 

“Indemnifying
Party” shall have the meaning set forth in Section 5(c).

 

“Initial
Registration Statement” means the initial Registration Statement filed pursuant to this Agreement.

 

“Losses”
shall have the meaning set forth in Section 5(a).

 

“Plan
of Distribution” shall have the meaning set forth in Section 2(a).

 

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the
Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to
the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference
in such Prospectus.

 

“Registrable
Securities” means, as of any date of determination, (a) all Shares, (b) all Warrant Shares then issued and issuable upon
exercise of the Warrants (assuming on such date the Warrants are exercised in full without regard to any exercise limitations
therein), and (c) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or
similar event with respect to the foregoing; provided, however, that any such Registrable Securities shall cease to be
Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration
Statement hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable
Securities is declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by
the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously sold in
accordance with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions and
without current public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed,
delivered and acceptable to the Transfer Agent and the affected Holders (assuming that such securities and any securities issuable
upon exercise, conversion or exchange of which, or as a dividend upon which, such securities were issued or are issuable, were at no
time held by any Affiliate of the Company), as reasonably determined by the Company, upon the advice of counsel to the Company.

 

    2 

     

    

 

“Registration
Statement” means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration
statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such
registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated
by reference or deemed to be incorporated by reference in any such registration statement.

 

“Rule
415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.

 

“Selling
Stockholder Questionnaire” shall have the meaning set forth in Section 3(a).

 

“SEC Guidance”
means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission
staff and (ii) the Securities Act.

 

    3 

     

    

 

2.        Shelf
Registration.

 

(a)               On
or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of
all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on
a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is
not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another
appropriate form in accordance herewith, subject to the provisions of Section 2(e)) and shall contain (unless otherwise directed by
at least 85% in interest of the Holders) substantially the “Plan of Distribution” attached hereto as Annex
A and substantially the “Selling Stockholder” section attached hereto as Annex B; provided, however,
that no Holder shall be required to be named as an “underwriter” without such Holder’s express prior written
consent. Subject to the terms of this Agreement, the Company shall use its reasonable best efforts to cause a Registration Statement
filed under this Agreement (including, without limitation, under Section 3(c)) to be declared effective under the Securities Act as
promptly as possible after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its
reasonable best efforts to keep such Registration Statement continuously effective under the Securities Act until the date that all
Registrable Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be
sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in
compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a
written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders (the
 “Effectiveness Period”). The Company shall telephonically request effectiveness of a Registration Statement as of
5:00 p.m. (New York City time) on a Trading Day. The Company shall promptly notify the Holders via e-mail of the effectiveness of a
Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with the Commission. The
Company shall timely file a final Prospectus with the Commission as required by Rule 424. Failure to so notify the Holder within one
(1) Trading Day of such notification of effectiveness or failure to timely file a final Prospectus as foresaid shall be deemed an
Event under Section 2(d).

 

(b)              
 Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the
Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single
registration statement, the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts
to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities
permitted to be registered by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities
as a secondary offering, subject to the provisions of Section 2(e); with respect to filing on Form S-3 or other appropriate form, and
subject to the provisions of Section 2(d) with respect to the payment of liquidated damages; provided, however, that prior
to filing such amendment, the Company shall be obligated to use diligent efforts to advocate with the Commission for the registration
of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation
612.09.

 

    4 

     

    

 

(c)               Notwithstanding
any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section 2(d), if the Commission
or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a
particular Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate
with the Commission for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in
writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration
Statement will be reduced as follows:

 

		a.	First,
                                            the Company shall reduce or eliminate any securities to be included other than Registrable
                                            Securities;

 

		b.	Second,
                                            the Company shall reduce Registrable Securities represented by Warrant Shares (applied, in
                                            the case that some Warrant Shares may be registered, to the Holders on a pro rata basis based
                                            on the total number of unregistered Warrant Shares held by such Holders); and 

 

		c.	Third,
                                            the Company shall reduce Registrable Securities represented by Shares (applied, in the case
                                            that some Shares may be registered, to the Holders on a pro rata basis based on the total
                                            number of unregistered Shares held by such Holders). 

 

In
the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days prior written notice along with the
calculations as to such Holder’s allotment. In the event the Company amends the Initial Registration Statement in accordance with
the foregoing, the Company will use its best efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance
provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form
available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement,
as amended.

 

    5 

     

    

 

(d)               If:
(i) the Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial Registration
Statement without affording the Holders the opportunity to review and comment on the same at least two Trading Days prior to filing,
the Company shall be deemed to have not satisfied this clause (i)), or (ii) the Company fails to file with the Commission a request
for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities
Act, within five Trading Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the
Commission that such Registration Statement will not be “reviewed” or will not be subject to further review, or (iii)
prior to the effective date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond
in writing to comments made by the Commission in respect of such Registration Statement within ten (10) calendar days after the
receipt of comments by or notice from the Commission that such amendment is required in order for such Registration Statement to be
declared effective, or (iv) a Registration Statement registering for resale all of the Registrable Securities is not declared
effective by the Commission by the Effectiveness Date of the Initial Registration Statement, or (v) after the effective date of a
Registration Statement, such Registration Statement ceases for any reason to remain continuously effective as to all Registrable
Securities included in such Registration Statement, or the Holders are otherwise not permitted to utilize the Prospectus therein to
resell such Registrable Securities, for more than fifteen (15) consecutive calendar days or more than an aggregate of twenty (20)
calendar days (which need not be consecutive calendar days) during any 12-month period (any such failure or breach being referred to
as an “Event”, and for purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose of
clause (ii) the date on which such five (5) Trading Day period is exceeded, and for purpose of clause (iii) the date which such ten
(10) calendar day period is exceeded, and for purpose of clause (v) the date on which such fifteen (15) or twenty (20) calendar day
period, as applicable, is exceeded being referred to as “Event Date”), then, in addition to any other rights the
Holders may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each such Event Date
(if the applicable Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to each
Holder an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 2.0% multiplied by the
aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement. The parties agree that the maximum aggregate
liquidated damages payable to a Holder under this Agreement shall be 12.0% of the aggregate Subscription Amount paid by such Holder
pursuant to the Purchase Agreement. If the Company fails to pay any partial liquidated damages pursuant to this Section in full
within seven days after the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such lesser maximum
amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated damages
are due until such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms
hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event. For purposes of an Event
arising under clause (i) of this section 2(d) caused by the Company’s failure provide the Holders with at least two Trading
Days to review on the Initial Registration Statement, the Event shall be deemed cured upon the subsequent filing of the Initial
Registration Statement.

 

(e)              
If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register
the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form
S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then
in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by
the Commission.

 

    6 

     

    

 

(f)               
 Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or affiliate
of a Holder as any Underwriter without the prior written consent of such Holder.

 

3.        Registration
Procedures.

 

In connection with the Company’s
registration obligations hereunder, the Company shall:

 

(a)              
Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior
to the filing of any amendment or supplement thereto (including any document that would be incorporated or deemed to be incorporated
therein by reference), the Company shall (i) furnish to each Holder copies of all such documents proposed to be filed, which documents
(other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such Holders, and (ii) cause
its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary,
in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities
Act. The Company shall not file a Registration Statement or any amendments or supplements thereto to which the Holders of a majority
of the Registrable Securities shall reasonably object in good faith, provided that, the Company is notified of such objection in writing
no later than five (5) Trading Days after the Holders have been so furnished copies of a Registration Statement or one (1) Trading Day
after the Holders have been so furnished copies of any amendments or supplements thereto. Each Holder agrees to furnish to the Company
a completed questionnaire in the form attached to this Agreement as Annex B (a “Selling Stockholder Questionnaire”)
on a date that is not less than two (2) Trading Days prior to the Filing Date or by the end of the fourth (4th) Trading Day
following the date on which such Holder receives draft materials in accordance with this Section.

 

(b)               (i)
Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the
Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the
applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration
Statements in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related
Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so
supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments received
from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably possible
to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration Statement
(provided that, the Company shall excise any information contained therein which would constitute material non-public information
regarding the Company or any of its Subsidiaries), and (iv) comply in all material respects with the applicable provisions of the
Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration
Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of
disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so
supplemented.

 

    7 

     

    

 

(c)              
If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common
Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior
to the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the number of
such Registrable Securities.

 

(d)               Notify
the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied
by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably
possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such
Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any
Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed, (B) when the Commission
notifies the Company whether there will be a “review” of such Registration Statement and whenever the Commission
comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective
amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental
authority for amendments or supplements to a Registration Statement or Prospectus or for additional information, (iii) of the
issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a
Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv)
of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from
qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding
for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a
Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any
document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any
revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the
Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading, and (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the
Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to
allow continued availability of a Registration Statement or Prospectus; provided, however, that in no event shall any
such notice contain any information which would constitute material, non-public information regarding the Company or any of its
Subsidiaries.

 

    8 

     

    

 

(e)              
Use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending
the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of
the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

 

(f)               
Upon request, furnish to each Holder, without charge, at least one conformed copy of each such Registration Statement and each
amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference
to the extent requested by such Person, and all exhibits to the extent requested by such Person (including those previously furnished
or incorporated by reference) promptly after the filing of such documents with the Commission, provided that any such item which is available
on the EDGAR system (or successor thereto) need not be furnished in physical form.

 

(g)              
Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement
thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus
and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).

 

(h)              
 Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or
cooperate with the selling Holders in connection with the registration or qualification (or exemption from the Registration or qualification)
of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United
States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during
the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions
of the Registrable Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally
to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction
where it is not then so subject or file a general consent to service of process in any such jurisdiction.

 

    9 

     

    

 

(i)                
 If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing
Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the
extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations
and registered in such names as any such Holder may request.

 

(j)                
Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking
into account the Company’s good faith assessment of any adverse consequences to the Company and its stockholders of the premature
disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement
to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required
document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading. If the Company notifies the
Holders in accordance with clauses (iii) through (vi) of Section 3(d) above to suspend the use of any Prospectus until the requisite
changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will use its best efforts
to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company shall be entitled to exercise its
right under this Section 3(j) to suspend the availability of a Registration Statement and Prospectus, subject to the payment of partial
liquidated damages otherwise required pursuant to Section 2(d), for a period not to exceed 60 calendar days (which need not be consecutive
days) in any 12-month period.

 

(k)              
Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the
Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including
any supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holders in
writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a
result thereof, the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take
such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.

 

(l)                
The Company shall use its reasonable best efforts to maintain eligibility for use of Form S-3 (or any successor form thereto)
for the registration of the resale of Registrable Securities.

 

    10 

     

    

 

(m)            
 The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common
Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive
control over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration
of the Registrable Securities solely because any Holder fails to furnish such information within three Trading Days of the Company’s
request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise
occur solely because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company.

 

4.        Registration
Expenses. All fees and expenses incident to the performance of or compliance with, this Agreement by the Company shall be borne by
the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to
in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees
and expenses of the Company’s counsel and independent registered public accountants) (A) with respect to filings made with the
Commission, (B) with respect to filings required to be made with any Trading Market on which the Common Stock is then listed for trading,
and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without
limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable
Securities), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities), (iii)
messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance,
if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with
the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal
expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation,
all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the
fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder.
In no event shall the Company be responsible for any broker or similar commissions of any Holder or, except to the extent provided for
in the Transaction Documents, any legal fees or other costs of the Holders.

 

    11 

     

    

 

5.        Indemnification.

 

(a)               Indemnification
by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder,
the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as
principal as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees
(and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or
any other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other
Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other
title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses,
claims, damages, liabilities, costs (including, without limitation, reasonable attorneys’ fees) and expenses (collectively,
 “Losses”), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material
fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in
any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be
stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the
circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company of the Securities
Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the performance of its
obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or omissions are
based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or
to the extent that such information relates to such Holder or such Holder’s proposed method of distribution of Registrable
Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement, such
Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this
purpose) or (ii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), the use by such Holder of
an outdated, defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus
is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice
contemplated in Section 6(c). The Company shall notify the Holders promptly of the institution, threat or assertion of any
Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such
indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person and
shall survive the transfer of any Registrable Securities by any of the Holders in accordance with Section 6(f).

 

    12 

     

    

 

(b)               Indemnification
by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers,
agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of
the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by
applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged
untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement
thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact
required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in
light of the circumstances under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue
statement or omission is contained in any information so furnished in writing by such Holder to the Company expressly for inclusion
in such Registration Statement or such Prospectus or (ii) to the extent, but only to the extent, that such information relates to
such Holder’s information provided in the Selling Stockholder Questionnaire or the proposed method of distribution of
Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration
Statement (it being understood that the Holder has approved Annex A hereto for this purpose), such Prospectus or in any amendment or
supplement thereto. In no event shall the liability of a selling Holder be greater in amount than the dollar amount of the proceeds
(net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any damages such
Holder has otherwise been required to pay by reason of such untrue statement or omission) received by such Holder upon the sale of
the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.

 

(c)              
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is
sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume the defense
thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses
incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve
the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be
finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure
shall have materially and adversely prejudiced the Indemnifying Party.

 

    13 

     

    

 

An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying
Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the
defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3)
the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying
Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the
same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies
the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the
Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one
separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement
of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed. No
Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending
Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such
Indemnified Party from all liability on claims that are the subject matter of such Proceeding.

 

Subject to the
terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent
incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall
be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided
that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such
actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject
to appeal or further review) not to be entitled to indemnification hereunder.

 

(d)              
Contribution. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient
to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by
such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified
Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations.
The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether
any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material
fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount
paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement,
any reasonable attorneys’ or other fees or expenses incurred by such party in connection with any Proceeding to the extent such
party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such
party in accordance with its terms.

 

    14 

     

    

 

The parties hereto
agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or
by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding
paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the dollar amount
of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any
damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission)
received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.

 

The indemnity and
contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified
Parties.

 

6.        Miscellaneous.

 

(a)              
Remedies. In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement,
each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement,
including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and
each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it
of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect
of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.

 

(b)              
No Piggyback on Registrations; Prohibition on Filing Other Registration Statements. Except as set forth on Schedule
6(b) attached hereto, neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto)
may include securities of the Company in any Registration Statements other than the Registrable Securities. The Company shall not file
any other registration statements until all Registrable Securities are registered pursuant to a Registration Statement that is declared
effective by the Commission, provided that this Section 6(b) shall not prohibit the Company from filing amendments to registration statements
filed prior to the date of this Agreement so long as no new securities are registered on any such existing registration statements.

 

(c)               Discontinued
Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of
the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue
disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the
 “Advice”) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended)
may be resumed. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is
practicable. The Company agrees and acknowledges that any periods during which the Holder is required to discontinue the disposition
of the Registrable Securities hereunder shall be subject to the provisions of Section 2(d).

 

    15 

     

    

 

(d)              
Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended,
modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be
in writing and signed by the Company and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of
clarification, this includes any Registrable Securities issuable upon exercise or conversion of any Security), provided that, if any
amendment, modification or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately
impacted Holder (or group of Holders) shall be required. If a Registration Statement does not register all of the Registrable Securities
pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered
for each Holder shall be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable
Securities shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions
hereof with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly
affect the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver
or consent relates; provided, however, that the provisions of this sentence may not be amended, modified, or supplemented
except in accordance with the provisions of the first sentence of this Section 6(d). No consideration shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered
to all of the parties to this Agreement.

 

(e)              
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be delivered as set forth in the Purchase Agreement.

 

(f)               
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns
of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations
hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign
their respective rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase Agreement.

 

(g)               No
Inconsistent Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the
Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities,
that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the
provisions hereof. Except as set forth on Schedule 6(i), neither the Company nor any of its Subsidiaries has previously
entered into any agreement granting any registration rights with respect to any of its securities to any Person that have not been
satisfied in full.

 

    16 

     

    

 

(h)              
Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together
shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered
to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered
by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding
obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile
or “.pdf” signature page were an original thereof.

 

(i)                
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall
be determined in accordance with the provisions of the Purchase Agreement.

 

(j)                
Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.

 

(k)              
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.

 

(l)                
Headings. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall
not be deemed to limit or affect any of the provisions hereof.

 

    17 

     

    

 

(m)             Independent
Nature of Holders’ Obligations and Rights. The obligations of each Holder hereunder are several and not joint with the
obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of
any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action
taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint
venture or any other kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a
group or entity with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the
Company acknowledges that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with
respect to such obligations or transactions. Each Holder shall be entitled to protect and enforce its rights, including without
limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an
additional party in any proceeding for such purpose. The use of a single agreement with respect to the obligations of the Company
contained was solely in the control of the Company, not the action or decision of any Holder, and was done solely for the
convenience of the Company and not because it was required or requested to do so by any Holder. It is expressly understood and
agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and not between the Company and
the Holders collectively and not between and among Holders.

 

********************

 

(Signature
Pages Follow)

 

    18 

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Registration Rights Agreement as of the date first written above.

 

	 	ROCKWELL MEDICAL, INC.    
	 	 
	 	By:	/s/ Russell Ellison
	 	 	Name: Russell Ellison 
	 	 	Title: Chief Financial Officer

  

[SIGNATURE PAGE OF HOLDERS FOLLOWS]

 

     

     

    

 

[SIGNATURE
PAGE OF HOLDERS TO RRA]

 

 

Name of Holder: Armistice Capital Master Fund Ltd.

 

	Signature of Authorized Signatory of Holder:	/s/ Steven Boyd	 

 

Name of Authorized Signatory: Steven Boyd

 

Title of Authorized Signatory: CIO of Armistice Capital, LLC, the
Investment ManagerExhibit
10.1

 

MASTER
AGREEMENT FOR THE OPERATIONAL AND TECHNOLOGY

FUNDING
OF NANOSYNEX LTD.

 

THIS
MASTER AGREEMENT FOR THE OPERATIONAL AND TECHNOLOGY FUNDING OF NANOSYNEX LTD. (this “Agreement”), dated as of May
26, 2022, is entered into by and among NanoSynex Ltd., a company incorporated under the laws of the State of Israel (the “Company”)
and Qualigen Therapeutics Inc. a Delaware corporation based in California, U.S., (the “Funder”).

 

R
E C I T A L S

 

WHEREAS,
the Company is seeking additional financing in order to fund its day-to-day operations and advancement of its technology; and

 

WHEREAS,
the Funder is a majority owner of the Company and desires to protect and grow the value of its investment in the Company by providing
ongoing funding to the Company to support the operational and technology development of the Company; and

 

WHEREAS,
each of the Entitled Holder of the Company (as defined in the Company’s then current articles of association, as may be amended
from time to time (the “Articles”), has waived all Pre-emptive Rights (as defined in the Articles) with regards to
any participation in the ongoing funding of the Company in an amount of up to US$10,420,000 (the “Aggregate Funding Amount”)
all subject to and in accordance with the terms and conditions set forth in this Agreement.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged and intending to be legally
bound, the parties hereto agree as follows:

 

1.
The Ongoing Funding.

 

1.1.
The Ongoing Funding Amount. Subject to the terms and conditions of this Agreement, the Funder shall pay to the Company a portion of the
Aggregate Funding Amount, as set forth in Exhibit A hereto (each, an “Installment Funding Amount”), on such
dates and subject to the achievement of the applicable milestones associated with each such Installment Funding Amount, as set forth
in Exhibit A hereto (each such payment date, an “Installment Date”). At each Installment Date, the Company
shall issue to Funder, a promissory note (which may contain convertible features) with a face value in the amount of the Installment
Funding Amount paid by Funder to the Company on such Installment Date, in substantially the form attached as Exhibit B hereto
(each a “Note” and together the “Notes”).

 

1.2.
On or prior to each Installment Date, the management of the Company shall deliver to the Funder a written notice of the achievement of
the milestone/s applicable to such Installment Date (the “Completion Notice”) and unless the Funder objects to, disputes
or disagrees with the Completion Notice (the “Dispute”), then the Funder shall provide the Installment Funding Amount
within 3 business days following the receipt of the Completion Notice against the issuance and execution of the corresponding Note (each,
an “Installment Closing”). To the extent that there is a Dispute, then the Funder shall provide the Company with a
written notice which shall include, in reasonable detail, the basis for such Dispute (the “Objection Notice”). Funder
shall be deemed to agree that the applicable milestone/s applicable to a particular Installment Date have been successfully achieved
if it has not provided to the Company an Objection Notice within 7 days of receipt of the Company’s Notice. In the event that the
Funder shall have provided an Objection Notice, the Company and the Funder shall use their commercially reasonable efforts to resolve
the Dispute with respect to the Completion Notice (and the milestone fulfillment) in an amicable manner. If the Funder and the Company
are not able to reach an understanding with respect to the achievement of the milestone/s pursuant to which a Completion Notice has been
delivered to the Funder within 7 days of delivery of the Objection Notice to the Company, the items in Dispute shall be referred to an
independent expert, who shall be agreed upon between the parties (the “Expert”) for final determination within 30
days after the date of such referral. If the Funder and the Company shall fail to agree upon the identity of such Expert within 7 days,
then the Expert shall be appointed by the Head of the Israel Bar Association. This provision for arbitration shall be specifically enforceable
by the parties, and the determination of the Expert in accordance with the provisions hereof shall be final and binding upon the Company
and the Funder with no right of appeal therefrom. The costs of the Expert shall be borne as to one-half by the Company, and as to one-half,
by the Funder.

 

    	 

     

    

 

1.3.
It is agreed that in the event that certain milestone/s have not been achieved on or before the applicable Installment Date (“Missed
Installment Date”), and such milestone/s have been achieved on or prior to the subsequent Installment Date, then the Funder
shall provide the Company the respective Installment Funding Amount for the Missed Installment Date on such subsequent Instalment Date
(in addition to any Installment Funding Amount owed with respect to such subsequent Installment Date).

 

2.
Closing; Transfer of Funding Amount.

 

2.1.
The initial closing under this Agreement shall be held remotely via the exchange of documents and signatures simultaneously with the
Closing under the Series B Preferred Share Purchase Agreement between the Company and Funder, dated as of April 29, 2022 (the “Series
B SPA”) (such date, the “Initial Closing”). At the Initial Closing, the Company shall deliver to the Funder:
(i) true and correct copies of the necessary resolutions of the Company’s Board of Directors and shareholders approving, inter
alia, this Agreement and the transactions contemplated hereby; and (ii) waivers of rights of preemption or other participation rights,
executed by all entitled to such rights under the Articles, or confirmation by the Company that any shareholder entitled to such rights
under the Articles that have not executed such waiver, failed to duly exercise such right with respect to the Agreement and the transactions
contemplated herein such that such right has irrevocably lapsed with respect hereof.

 

3.
Representations and Warranties of the Company

 

The
Company’s representations and warranties under Section 3 to the Series B SPA, are hereby fully incorporated by reference (the “Reps”)
and the Company hereby represents and warrants the Reps to Funder as of the Initial Closing.

 

4.
Representations and Warranties of the Funder.

 

The
Funder represents and warrants to the Company that it has knowledge and experience in financial and business matters, is capable of evaluating
the merits and risks of the transactions evidenced by this Agreement, can bear the economic consequences of such investment for an indefinite
period of time, has been furnished with all information it has requested and been afforded the opportunity to ask questions concerning
the Company. The Funder further acknowledges that the Company is an early-stage company, engaging in speculative research and development
and that that there are substantial risks of loss of investment incidental to the transactions contemplated by this Agreement. The Funder
is an “accredited investor” within the meaning of Regulation D of the Securities Act of 1933, as amended. The foregoing shall
not derogate from the Company’s representations in Section 3 above.

 

5.
Conditions to Funding by the Funder

 

The
obligations of the Funder to pay the applicable Installment Funding Amount at each Installment Closing is subject to the fulfillment
on or before the Initial Closing and each subsequent Installment Closing (as applicable) of each of the following conditions, the waiver
of which shall not be effective unless given by the Funder in writing:

 

5.1.
Each of the Reps are true and correct as of the date of this Agreement and shall be true and correct on and as of the Initial Closing.

 

5.2.
No Company Material Adverse Effect has occurred or exists since the date of this Agreement and as of the Initial Closing and each subsequent
Installment Closing. “Material Adverse Effect” means (i) any event, occurrence, fact, condition, change or development that
has had or could reasonably be expected to have, either alone or together with other events, occurrences, facts, conditions, changes
or developments, a material adverse effect on the business, properties, assets, key employees, operations, results of operations, condition
(financial or otherwise), prospects, assets or liabilities of the Company; (ii) any event, occurrence, fact, condition, change or development
that prevents, materially impairs or materially delays the Company’s ability to conduct the Company’s business as it is now
being conducted and as presently proposed to be conducted, (iii) any of the following Reps is not true and correct in all material respects
as of each Installment Closing, with the exception of non-adverse ordinary course changes in the Reps due to ordinary course development
and progress of the business following the initial Closing : Section 3.1 (“Organization; Permits”), Section 3.2 (“Share
Capital”), Section 3.7 (“Authorization; Approvals”), Section 3.8 (“No Breach”), Section
3.10 (“Intellectual Property and Other Intangible Assets”), Section 3.11 (“Taxes”), Section 3.24
(“Preclinical Development and Clinical Trials”), and Section 3.25 (“Regulatory Permits and Compliance”)
(all as set forth in the Series B SPA); or (iv) either of the following covenants is not true and correct as of each Installment Closing:
Section 7.4 (“Controlled Foreign Corporation”) and 7.5 (“Passive Foreign Investment Company”).

 

    	2

     

    

 

5.3.
The Company has performed and complied with each of the covenants and obligations under this Agreement and/or the Notes required to be
performed and complied with by the Company prior to or as of the Initial Closing and each subsequent Installment closing.

 

6.
Affirmative Covenants

 

6.1.
Company shall not distribute and/or declare any dividend from the date of this Agreement and until the last subsequent Installment closing
under this Agreement.

 

6.2.
So long as this Agreement and/or any of the Notes remain outstanding, the Company undertakes not to create or permit to subsist any mortgage,
charge, pledge, lien or other encumbrance upon any or all of its present or future assets to secure any present or future Bond Issue
without at the same time, or prior thereto, securing the Notes equally and rateably therewith. “Bond Issue” means any indebtedness
of the Company which is, in the form of, or is represented by, any bond, security, certificate or other instrument which is or is capable
of being listed, quoted or traded on any stock exchange or in any securities market (including any over-the-counter market) and any guarantee
or other indemnity in respect of such indebtedness.

 

7.
Termination.

 

Notwithstanding
anything to the contrary in this Agreement, Funder may terminate this Agreement at any time following the date that is six (6) months
after the date of this Agreement in its sole discretion (“Termination”) upon 120 days’ notice (the “Termination
Notice Period”); provided however, such termination shall not limit Funder’s obligation to pay any non-disputed Installment
Funding Amount that otherwise becomes due under this Agreement during the Termination Notice Period as a result of the Company’s
having completed or substantially completed Milestones prior to or during the Termination Notice Period; and provided further, that if
such Termination is due to a Material Adverse Effect under Section 5(1), the notice of Termination may be delivered immediately upon
such occurrence, including during the first six (6) months following the date of this Agreement, and the required Termination Notice
Period shall be 20 days instead of 120 days. The Company’s sole recourse in the event Funder terminates this Agreement in accordance
with this Section 7 shall be pursuant to this Section 7 and Article 46 of the Company’s Articles relating to the removal of a Funder-appointed
director to the Company’s board of directors.

 

8.
Miscellaneous.

 

8.1.
Taxes. Out of any amount payable by the Company to the Funder under any Note issued by the Company to the Funder pursuant to this
Agreement, the Company shall withhold tax at the rate provided by applicable law and shall transfer such withheld tax to the Israeli
Tax Authority, unless otherwise specified in any tax certificate issued by the Israeli Tax Authority, in which case the Company shall
withhold tax as provided in such tax certificate. To the extent that amounts are so withheld and paid to the Israeli Tax Authority by
the Company, such withheld amounts shall be treated for all purposes of this Agreement as having been paid by the Company to the Funder,
in accordance with the provisions of this Agreement. Upon conversion of any portion of a Note issued by the Company to the Funder to
Preferred Shares pursuant to the terms of such Note, the Funder, at its sole discretion, shall be entitled to waive the repayment of
its respective Interest thereon. Alternatively, in the event that the Funder does not wish to waive the repayment of its respective Interest,
the Funder shall either, at his election: (i) transfer to the Company a certificate issued by the Israeli Tax Authority which exempts
the Company from withholding tax with respect to such respective Interest; (ii) transfer to the Company an amount equal to the applicable
withholding tax on such respective Interest, in order for the Company to transfer such amount to the Israeli Tax Authority (on account
of withheld tax) or (iii) convert only Principal amount (and not Interest thereon).

 

    	3

     

    

 

8.2.
Further Assurances. Each of the parties hereto shall perform such further acts and execute such further documents as may reasonably
be necessary to carry out and give full effect to the provisions of this Agreement and the intentions of the parties as reflected hereby,
including, without limitation, to create, reserve or approve any action for the creation or reservation (as applicable) of a sufficient
type and number of securities of the Company to allow the conversion of the Funding Amount (or the portion thereof actually invested)
pursuant to the terms of this Agreement.

 

8.3.
Governing Law; Jurisdiction. This Agreement shall be governed by and construed and interpreted according to the laws of the State
of Israel, without regard to the conflict of laws provisions thereof. Any dispute arising under or in relation to this Agreement shall
be resolved exclusively in the competent courts located in Tel Aviv, Israel, and each of the parties hereby irrevocably submits to the
exclusive jurisdiction of such courts.

 

8.4.
Entire Agreement; Amendment and Waiver. This Agreement constitutes the full and entire understanding and agreement between the
parties with regard to the subject matter hereof and supersedes any prior agreements between the parties with respect to such subject
matter. Any term of this Agreement may be amended, and the observance of any term hereof may be waived (either prospectively or retroactively
and either generally or in a particular instance) only with the written consent of the Company and the Funder.

 

8.5.
Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed
effectively given upon the earlier of actual receipt or: (a) upon personal delivery to the party to be notified, (b) on the first business
day following delivery after having been sent by electronic mail (with electronic confirmation of delivery), (c) five (5) days after
having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after deposit
with a nationally recognized overnight courier, specifying next business day delivery, with written verification of receipt. Delays or
Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party upon any breach or default under this Agreement,
shall be deemed a waiver of any other breach or default theretofore or thereafter occurring.

 

8.6.
Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable under applicable
law, then such provision shall be excluded from this Agreement and the remainder of this Agreement shall be interpreted as if such provision
were so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Agreement shall be
interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and intention
of the excluded provision as determined by such court of competent jurisdiction.

 

8.7.
Counterparts. This Agreement may be executed and delivered in one or more counterparts, each of which shall be deemed an original
and all of which together shall constitute one instrument. Signed counterparts of this Agreement may be delivered by facsimile and by
scanned pdf. image.

 

8.8.
Successors and Assigns. This Agreement may not be assigned by either party without the consent of the Company (if by an Funder)
or the Funder (if by the Company), however, Funder may assign or transfer its rights, privileges, or obligations set forth in, arising
under, or created by this Agreement to its “Permitted Transferees” as defined in the Articles, provided, however, that any
such Permitted Transferee agrees in writing, prior to or at such assignment or transfer, to be bound by all agreements, warranties and
representations binding upon such Funder under this Agreement.

 

8.9.
Survival of Representations and Warranties. All agreements, representations and warranties contained herein shall survive the
execution and delivery of this Agreement and the closing of the transactions contemplated hereby without regard to any investigation
or discovery made by the Funder or knowledge of the subject matter thereof. None of the Funder’s rights under this Agreement will
be limited or otherwise affected by any imputed knowledge or knowledge obtained by the Funder at any time before or after the Initial
Closing with respect to any inaccuracy of any of the Reps.

 

[Remainder
of page intentionally left blank]

 

    	4

     

    

 

IN
WITNESS WHEREOF, the parties have signed this Agreement as of the date first written above.

 

	THE
    COMPANY:	 
	 	 
	NANOSYNEX
    LTD.	 
	 	 	 
	By:	/s/
    Diane Abensur	 
	Name:	Diane
Abensur	 
	Title:	CEO	 

 

IN
WITNESS WHEREOF, the parties have signed this Agreement as of the date first written above.

 

	FUNDER:	 
	 	 
	QUALIGEN
    THERAPEUTICS INC.	 
	 	 	 
	By:	/s/
    Michael Poirier	 
	Name:	Michael
    Poirier	 
	Title:	Chairman
    & CEO	 

 

    	 

     

    

 

Exhibit
A

 

Schedule
of Installments

 

Schedule
has been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy will be furnished to the SEC upon request.

 

    	 

     

    

 

Exhibit
B

 

Form
of Note

 

THIS
NOTE HAS BEEN ISSUED WITHOUT REGISTRATION OR QUALIFICATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES
LAWS AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF WITHOUT SUCH REGISTRATION AND QUALIFICATION, OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE ISSUER IN FORM AND SUBSTANCE THAT SUCH SALE, TRANSFER, OR DISPOSITION MAY LAWFULLY BE MADE WITHOUT REGISTRATION
OR QUALIFICATION.

 

FOR
PURPOSES OF THE UNITED STATES INTERNAL REVENUE CODE OF 1986, AS AMENDED, THIS NOTE IS ISSUED WITH ORIGINAL ISSUE DISCOUNT. THE HOLDER
OF THIS NOTE MAY CONTACT [INSERT NAME OF THE APPROPRIATE REPRESENTATIVE OF THE COMPANY] AT [INSERT PHONE NUMBER], WHO WILL, NOT LATER
THAN TEN DAYS AFTER THE DATE HEREOF, PROMPTLY MAKE AVAILABLE TO HOLDERS, UPON REQUEST, THE FOLLOWING INFORMATION: (1) THE ISSUE PRICE
AND ISSUE DATE OF THIS NOTE, (2) THE AMOUNT OF ORIGINAL ISSUE DISCOUNT ON THIS NOTE, AND (3) THE YIELD TO MATURITY OF THIS NOTE.

 

	PROMISSORY
    NOTE
	US
    $[______]	_____
    __, 2022

 

FOR
VALUE RECEIVED, NanoSynex Ltd., a company incorporated under the laws of the State of Israel (the “Company”), hereby
promises to pay to Qualigen Therapeutics Inc. (the “Funder”), a Delaware company based in California, U.S., in the
manner hereinafter specified, the principal sum of [_____] US Dollars ($[____],000.00) (the “Principal”), together
with interest from the date hereof at a rate of 9.00% per annum on the principal balance from time to time outstanding (the “Interest”).
Principal and Interest due under this Promissory Note (the “Note”) shall be due and payable in lawful money of the
United States. Payments hereunder shall be made via wire transfer to the Funder’s bank account as set forth in Exhibit A attached
hereto or such other address as Funder may hereafter designate by written notice to Company.

 

This
Note is being made pursuant to that Master Agreement for the Operational and Technology Funding of NanoSynex Ltd. between Company and
Funder, dated April 29, 2022 (the “Funding Agreement”), and all terms set forth therein shall apply to this Note mutatis
mutandis.

 

1.
Payments.

 

a.
The Principal and Interest under this Note shall be due and payable upon the sooner to occur of: (i) five (5) years from the date of
this Note; (ii) the acquisition by any person or entity of all or substantially all of the share capital of Company, through share purchase,
issuance of shares or merger of the Company or the purchase of all or substantially all of the assets of Company; or (iii) the initial
public offering (“IPO”) of Company (the “Maturity Date”). All payments under this Note shall be
applied first to accrued but unpaid Interest, and next to outstanding Principal.

 

b.
Prepayment. Principal and accrued Interest due hereunder may be prepaid or paid in advance by Company in its sole discretion,
in whole or in part, at any time upon fifteen (15) days prior written notice without any premium or penalty imposed on Company.

 

    	 

     

    

 

2.
Conversion. If at any time, Funder’s ownership of the share capital of the Company on an issued and outstanding basis falls
or is reasonably expected to fall below 50.1%, solely as a result of the exercise of existing or future options (or an equivalent instrument)
or as a result of issuance of restricted, shares, restricted stock units (or an equivalent instruments) under the Company’s 2018
Share Option Plan or an equivalent plan adopted by the Company’s board of directors (a “Trigger Event”), Funder
may, in its sole discretion, convert all or any portion of the outstanding Principal amount (such portion of Principal amount that is
so converted, the “Convertible Amount”) into shares of the Company’s most senior class of Preferred Shares (as
such term is defined under the Company’s then current articles of association, as may be amended from time to time (the “Articles”)
existing immediately prior to such conversion. The number of such shares to be issued upon such conversion shall be equal to the quotient
obtained by dividing the Convertible Amount by a price per share equal to the higher of (i) the Original Issue Price of the Preferred
B Shares –(or the Conversion Price of the Preferred B Shares, if such Conversion Price is lower than the Original Issue Price)
(as such terms are defined in the Articles); and (ii) a price that reflects a discount of 20% (twenty percent) on the Original Issue
Price of the Company’s most senior class of Preferred Shares at the time of conversion that are issued in a bona fide financing,
so that, following such conversion, Funder shall regain 50.1% of Company’s issued and outstanding share capital. The Convertible
Amount shall be deemed to be repaid at the time of conversion. For as long as the Principal amount has not been repaid or converted in
full, the Company shall deliver a thirty (30) days prior written notice to the Funder, or shorter notice if thirty (30) days is not practically
possible, of any contemplated Trigger Event. The conversion right of the Funder described in this Section ‎2, shall not apply in
case the Funder’s ownership of the share capital of the Company on an issued and outstanding basis falls below 50.1% due to exercise
of options or an equivalent instrument immediately prior to, and contingent upon, a consummation of subsections (i), (ii) or (iii) of
the definition of a Deemed Liquidation (as such term is defined in the Articles).

 

3.
Default and Remedies. The occurrence of any one or more of the following events shall constitute an event of default under this
Note (an “Event of Default”): (i) if Company fails to pay when due any payment of Principal or Interest on this Note
or any other Note issued to Funder under the Funding Agreement and such failure continues for five (5) business days after the due date;
(ii) if, pursuant to or within the meaning of the United States Bankruptcy Code or any other applicable law of Company’s home jurisdiction
relating to insolvency or relief of debtors (the “Code”), Company (A) commences a voluntary case or proceeding; (B)
consents to the entry of an order for relief against it in an involuntary case; (C) consents to the appointment of a trustee, receiver,
assignee, liquidator, or similar official; or (D) makes an assignment for the benefit of its creditors; (iii) if a court of competent
jurisdiction enters an order or decree under the Code that (A) is for relief against Company in an involuntary case; (B) appoints a trustee,
receiver, assignee, liquidator, or similar official for Company, or substantially all of Company’s assets; or (C) orders the liquidation
of Company, and in each case the order or decree is not dismissed within sixty (60) days, which breach goes uncured for five (5) business
days after Funder notifies Company of such breach in writing; or (iv) Company becomes insolvent. Upon the occurrence of an Event of Default:

 

a.
All unpaid amounts under this Note shall, without notice, become immediately due and payable at the option of Funder (which may demand
immediate repayment of all or part of any unpaid amount);

 

b.
Funder shall have all rights and remedies under applicable law; and

 

c.
Interest shall accrue at the default rate of eighteen percent (18%) per annum.

 

4.
Revival. To the extent that Company makes a payment or Funder receives any payment or proceeds for Company’s benefit, which
are subsequently invalidated, declared to be fraudulent or preferential, set aside or required to be repaid to a trustee, debtor in possession,
receiver, custodian or any other party under the Code, then, to such extent, the obligations of Company hereunder intended to be satisfied
shall be revived and continue as if such payment or proceeds had not been received by Funder.

 

5.
Miscellaneous.

 

a.
Modifications and Amendments. The terms and provisions of this Note may be modified or amended only by written agreement executed
by Company and Funder.

 

b.
Assignment/Binding Effect. Neither this Note, nor any right hereunder, may be assigned by Company without the prior written consent
of Funder. This Note shall be binding upon, and inure to the benefit of, the parties hereto and their respective heirs, personal representatives,
successors and permitted assigns.

 

    	 	B-2	 

     

    

 

c.
Severability. In the event that any court of competent jurisdiction shall finally determine that any provision, or any portion
thereof, contained in this Note shall be void or unenforceable in any respect, then such provision shall be deemed limited to the extent
that such arbitral tribunal determines it enforceable, and as so limited shall remain in full force and effect. In the event that such
court shall determine any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Note shall nevertheless
remain in full force and effect.

 

d.
Interpretation. The parties hereto acknowledge and agree that: (i) the rule of construction to the effect that any ambiguities
are resolved against the drafting party shall not be employed in the interpretation of this Note, and (ii) the terms and provisions of
this Note shall be construed fairly as to all parties hereto and not in favor of or against any party, regardless of which party was
generally responsible for the preparation of this Note.

 

e.
Headings and Captions. The headings and captions of the various subdivisions of this Note are for convenience of reference only
and shall in no way modify, or affect, or be considered in construing or interpreting the meaning or construction of any of the terms
or provisions hereof.

 

f.
Governing Law; Jurisdiction. This Agreement shall be governed by and construed and interpreted according to the laws of the State
of Israel, without regard to the conflict of laws provisions thereof. Any dispute arising under or in relation to this Agreement shall
be resolved exclusively in the competent courts located in Tel Aviv, Israel, and each of the parties hereby irrevocably submits to the
exclusive jurisdiction of such courts.

 

g.
Notices. All notices and other communications given or made pursuant to this Note shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt or: (a) upon personal delivery to the party to be notified, (b) on the first business day following
delivery after having been sent by electronic mail (with electronic confirmation of delivery), (c) five (5) days after having been sent
by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally
recognized overnight courier, specifying next business day delivery, with written verification of receipt.

 

h.
Counterparts. This Note may be executed in any number of counterparts (including by email or electronic signature), each of which
shall be deemed an original and enforceable against the parties actually executing such counterpart, and all of which together shall
constitute one and the same instrument.

 

i.
Waivers. The Company and all others who may become liable for payment of all or any part of the obligations hereunder do hereby
severally waive presentment and demand for payment, protest, notice of nonpayment, notice of intent to accelerate the maturity hereof,
notice of protest, notice of dishonor and notice of maturity. Any delay by the Funder hereof in exercising any power or right hereunder
shall not operate as a waiver thereof, nor shall the exercise of any single or partial right hereunder create any other or further exercise
thereof or exercise of any other power or right, nor shall the Funder hereof be liable for exercising or failing to exercise any such
power or right. The rights, remedies and benefits herein specified are cumulative and not exclusive of any rights, remedies or benefits
which the Funder hereof otherwise may have.

 

[Signature
on following page]

 

    	 	B-3	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Note effective as of the date first above written.

 

	“COMPANY”	 
	 	 
	NANOSYNEX
    LTD.	 
	 	 	 
	By:	          	 

 

	“FUNDER”	 
	 	 
	QUALIGEN
    THERAPEUTICS INC.	 
	 	 	 
	By:	            	 
	Exhibit A	 
	Bank Account	 
	[___]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]